Literature DB >> 23636172

Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway.

Bertrand Gondouin1, Claire Cerini, Laetitia Dou, Marion Sallée, Ariane Duval-Sabatier, Anneleen Pletinck, Raymond Calaf, Romaric Lacroix, Noémie Jourde-Chiche, Stéphane Poitevin, Laurent Arnaud, Raymond Vanholder, Philippe Brunet, Françoise Dignat-George, Stéphane Burtey.   

Abstract

In chronic kidney disease (CKD), uremic solutes accumulate in blood and tissues. These compounds probably contribute to the marked increase in cardiovascular risk during the progression of CKD. The uremic solutes indoxyl sulfate and indole-3-acetic acid (IAA) are particularly deleterious for endothelial cells. Here we performed microarray and comparative PCR analyses to identify genes in endothelial cells targeted by these two uremic solutes. We found an increase in endothelial expression of tissue factor in response to indoxyl sulfate and IAA and upregulation of eight genes regulated by the transcription factor aryl hydrocarbon receptor (AHR). The suggestion by microarray analysis of an involvement of AHR in tissue factor production was confirmed by siRNA inhibition and the indirect AHR inhibitor geldanamycin. These observations were extended to peripheral blood mononuclear cells. Tissue factor expression and activity were also increased by AHR agonist dioxin. Finally, we measured circulating tissue factor concentration and activity in healthy control subjects and in patients with CKD (stages 3-5d), and found that each was elevated in patients with CKD. Circulating tissue factor levels were positively correlated with plasma indoxyl sulfate and IAA. Thus, indolic uremic solutes increase tissue factor production in endothelial and peripheral blood mononuclear cells by AHR activation, evoking a 'dioxin-like' effect. This newly described mechanism of uremic solute toxicity may help understand the high cardiovascular risk of CKD patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636172     DOI: 10.1038/ki.2013.133

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  102 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

2.  Dialysis Vascular Access Intervention and the Search for Biomarkers.

Authors:  Karl A Nath
Journal:  J Am Soc Nephrol       Date:  2015-10-09       Impact factor: 10.121

3.  Uremic Toxic Blood-Brain Barrier Disruption Mediated by AhR Activation Leads to Cognitive Impairment during Experimental Renal Dysfunction.

Authors:  Mickaël Bobot; Laurent Thomas; Anaïs Moyon; Samantha Fernandez; Nathalie McKay; Laure Balasse; Philippe Garrigue; Pauline Brige; Sophie Chopinet; Stéphane Poitevin; Claire Cérini; Philippe Brunet; Françoise Dignat-George; Stéphane Burtey; Benjamin Guillet; Guillaume Hache
Journal:  J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 10.121

4.  Regulation of tissue factor gene expression in monocytes and endothelial cells: Thromboxane A2 as a new player.

Authors:  Michael Bode; Nigel Mackman
Journal:  Vascul Pharmacol       Date:  2014-05-21       Impact factor: 5.773

5.  The uremic solute-AHR-tissue factor axis in vascular cells, mouse models and thrombosis in chronic kidney disease patients.

Authors:  Nigel Mackman; Jonathan H Erlich
Journal:  Ann Transl Med       Date:  2018-06

6.  The cardiovascular effect of the uremic solute indole-3 acetic acid.

Authors:  Laetitia Dou; Marion Sallée; Claire Cerini; Stéphane Poitevin; Bertrand Gondouin; Noemie Jourde-Chiche; Karim Fallague; Philippe Brunet; Raymond Calaf; Bertrand Dussol; Bernard Mallet; Françoise Dignat-George; Stephane Burtey
Journal:  J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 10.121

7.  Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk.

Authors:  Moshe Shashar; Mostafa E Belghasem; Shinobu Matsuura; Joshua Walker; Sean Richards; Faisal Alousi; Keshab Rijal; Vijaya B Kolachalama; Mercedes Balcells; Minami Odagi; Kazuo Nagasawa; Joel M Henderson; Amitabh Gautam; Richard Rushmore; Jean Francis; Daniel Kirchhofer; Kumaran Kolandaivelu; David H Sherr; Elazer R Edelman; Katya Ravid; Vipul C Chitalia
Journal:  Sci Transl Med       Date:  2017-11-22       Impact factor: 17.956

8.  Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling.

Authors:  Tacy Santana Machado; Stéphane Poitevin; Pascale Paul; Nathalie McKay; Noémie Jourde-Chiche; Tristan Legris; Annick Mouly-Bandini; Françoise Dignat-George; Philippe Brunet; Rosalinde Masereeuw; Stéphane Burtey; Claire Cerini
Journal:  J Am Soc Nephrol       Date:  2017-12-08       Impact factor: 10.121

Review 9.  The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review.

Authors:  Raymond Vanholder; Eva Schepers; Anneleen Pletinck; Evi V Nagler; Griet Glorieux
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

Review 10.  Thrombosis in the uremic milieu--emerging role of "thrombolome".

Authors:  Moshe Shashar; Jean Francis; Vipul Chitalia
Journal:  Semin Dial       Date:  2014-06-24       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.